Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GEHC
GEHC logo

GEHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
63.035
Open
62.750
VWAP
62.52
Vol
5.62M
Mkt Cap
28.36B
Low
62.190
Amount
351.10M
EV/EBITDA(TTM)
10.53
Total Shares
454.89M
EV
36.50B
EV/OCF(TTM)
18.02
P/S(TTM)
1.36
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
Show More

Events Timeline

(ET)
2026-05-12
09:10:00
GE HealthCare Showcases AI Solutions at 2026 Radiotherapy Congress
select
2026-05-11 (ET)
2026-05-11
09:10:00
GE HealthCare Launches Next-Gen MR Systems and Research Tools
select

News

Yahoo Finance
6.0
05-27Yahoo Finance
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
  • Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
  • Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
  • Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
  • Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
NASDAQ.COM
5.0
05-27NASDAQ.COM
MercadoLibre and GE Healthcare Executives Increase Stock Holdings
  • Executive Purchases: MercadoLibre Director Alejandro Nicolas Aguzin disclosed in an SEC filing that he bought 600 shares of MELI at $1,655.93 each on Friday, totaling an investment of $993,556, marking his first purchase in the past twelve months, indicating confidence in the company's future.
  • Market Reaction: Following the news of Aguzin's purchase, MercadoLibre's stock rose approximately 2.3% on Wednesday, reflecting a positive market response to insider buying, which may bolster investor confidence in the company's outlook.
  • GE Healthcare Purchase: On the same day, GE HealthCare Technologies Director Kevin Lobo purchased $641,800 worth of stock, acquiring 10,000 shares at $64.18 each, demonstrating confidence in the company's growth potential.
  • Profit Performance: As of Wednesday, Lobo's investment has yielded a gain of about 2.3%, based on the day's high trading price of $65.63, indicating market optimism for GE HealthCare, which could drive its stock price higher in the future.
Newsfilter
7.0
05-22Newsfilter
Investigation into GE HealthCare's Possible Securities Law Violations
  • Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
  • Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
  • Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
  • Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
Globenewswire
7.0
05-21Globenewswire
GE HealthCare Reports Q1 Earnings Miss, Shares Plunge
  • Earnings Report Miss: In Q1 2026, GE HealthCare reported adjusted EPS of $0.99, falling short of the $1.05 consensus estimate, indicating potential profitability challenges that could undermine investor confidence.
  • Guidance Downgrade: The company revised its full-year 2026 adjusted EPS guidance down to a range of $4.80 to $5.00 from the previous $4.95 to $5.15, reflecting a cautious outlook on future performance.
  • Significant Stock Decline: Following the earnings announcement, GE HealthCare's stock price plummeted from $68.50 to $59.49, a drop of approximately 13%, suggesting heightened market concerns regarding the company's prospects and prompting investors to reassess their positions.
  • Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by GE HealthCare and its senior management; while no lawsuits have been filed yet, this inquiry could further impact the company's reputation and stock price.
CNBC
6.0
05-21CNBC
Latest Wall Street Ratings Overview
  • SailPoint Coverage Initiation: Roth initiates coverage of SailPoint with a Buy rating and a price target of $19, highlighting its leadership in Identity Governance and Administration, which is expected to drive future growth potential.
  • Brown & Brown Market Outperform: Citizens initiates coverage of Brown & Brown with a Market Outperform rating and a $70 price target, indicating significant upside potential driven by strong market demand and business outlook.
  • Ameren Upgrade: JPMorgan upgrades Ameren from Neutral to Overweight, noting that the growing demand from data centers will enhance the company's earnings outlook, with a significant potential increase in EPS CAGR.
  • FedEx Rating Reinstatement: Citi reinstates a Buy rating on FedEx with a target price of $443, citing the company's strong performance amid macroeconomic shifts, solid execution, and value unlock from recent spin-offs.
Globenewswire
7.0
05-19Globenewswire
GE HealthCare Faces Investor Lawsuit Investigation
  • Earnings Miss: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026, falling short of the $1.05 consensus estimate, which led to a downward revision of its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability.
  • Stock Price Plunge: Following the disappointing earnings report, GE HealthCare's stock price dropped by $9.01, or approximately 13%, from $68.50 on April 28, 2026, to $59.49 on April 29, reflecting market concerns about the company's future performance.
  • Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether GE HealthCare has violated federal securities laws or engaged in other unlawful business practices, highlighting concerns regarding corporate governance and compliance.
  • Investor Rights Advocacy: The law firm is encouraging all investors who purchased GE HealthCare shares during this period and suffered losses to reach out, indicating potential risks and opportunities for compensation related to the company's legal liabilities.
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
Wall Street analysts forecast GEHC stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Evercore ISI
Outperform
to
Outperform
downgrade
$85 -> $80
AI Analysis
2026-04-30
Reason
Evercore ISI
Price Target
$85 -> $80
AI Analysis
2026-04-30
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on GE HealthCare to $80 from $85 and keeps an Outperform rating on the shares.
JPMorgan
Robbie Marcus
Neutral
downgrade
$80 -> $65
2026-04-30
Reason
JPMorgan
Robbie Marcus
Price Target
$80 -> $65
2026-04-30
downgrade
Neutral
Reason
JPMorgan analyst Robbie Marcus lowered the firm's price target on GE HealthCare to $65 from $80 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GEHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for GE Healthcare Technologies Inc (GEHC.O) is 13.09, compared to its 5-year average forward P/E of 17.98. For a more detailed relative valuation and DCF analysis to assess GE Healthcare Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
17.98
Current PE
13.09
Overvalued PE
19.99
Undervalued PE
15.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.41
Current EV/EBITDA
11.82
Overvalued EV/EBITDA
12.93
Undervalued EV/EBITDA
9.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.71
Current PS
1.26
Overvalued PS
1.97
Undervalued PS
1.45

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what should i buy
Intellectia · 41 candidates
Market Cap: >= 10.00BRegion: USMarket Cap Category: mega, largeNet Margin: >= 10.00Beta: ModerateRiskPe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.10T
GS logo
GS
Goldman Sachs Group Inc
277.81B
AXP logo
AXP
American Express Co
226.22B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
131.73B
AEM logo
AEM
Agnico Eagle Mines Ltd
108.41B
BMO logo
BMO
Bank of Montreal
108.32B
Show US
Intellectia · 35 candidates
Market Cap: >= 10.00BRegion: USBeta: ModerateRiskPe Ttm: 5 - 30Return On Equity: >= 10.0%Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.10T
HD logo
HD
Home Depot Inc
349.60B
GS logo
GS
Goldman Sachs Group Inc
277.81B
AXP logo
AXP
American Express Co
226.22B
ADBE logo
ADBE
Adobe Inc
100.50B
PNC logo
PNC
PNC Financial Services Group Inc
91.28B
je veux trader sur le nasdaq 100
Intellectia · 16 candidates
Price: $10.00 - $500.00Analyst Consensus: Strong Buy, Moderate BuyBeta: ModerateRiskIs Index Component: NDX
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.76T
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
NFLX logo
NFLX
Netflix Inc
324.56B
ISRG logo
ISRG
Intuitive Surgical Inc
172.54B
PDD logo
PDD
PDD Holdings Inc
142.36B
NASDAQ100 stock with fairly or undervalue
Intellectia · 10 candidates
Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15
Ticker
Name
Market Cap$
top bottom
FANG logo
FANG
Diamondback Energy Inc
44.13B
PDD logo
PDD
PDD Holdings Inc
152.56B
PYPL logo
PYPL
PayPal Holdings Inc
53.15B
BIIB logo
BIIB
Biogen Inc
25.32B
TMUS logo
TMUS
T-Mobile US Inc
211.11B
CTSH logo
CTSH
Cognizant Technology Solutions Corp
41.28B
how do i create a customized screener
Intellectia · 94 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midNet Margin: >= 5.00Beta: ModerateRiskPe Ttm: 10 - 30Return On Equity: >= 10.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PDD logo
PDD
PDD Holdings Inc
150.37B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
141.76B
AEM logo
AEM
Agnico Eagle Mines Ltd
103.10B
BMO logo
BMO
Bank of Montreal
96.25B
PNC logo
PNC
PNC Financial Services Group Inc
91.17B
USB logo
USB
US Bancorp
86.26B
show me stocks that have beta =0.8 Alfa =+5
Intellectia · 25 candidates
Market Cap: 20.00B - 50.00BBeta: ModerateRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
DHI logo
DHI
D.R. Horton Inc
45.93B
DAL logo
DAL
Delta Air Lines Inc
45.02B
KGC logo
KGC
Kinross Gold Corp
43.05B
EL logo
EL
Estee Lauder Companies Inc
42.48B
JD logo
JD
JD.com Inc
41.25B
TCOM logo
TCOM
Trip.com Group Ltd
40.50B

Whales Holding GEHC

C
Castle Hook Partners LP
Holding
GEHC
+19.49%
3M Return
M
Menora Mivtachim Provident Funds
Holding
GEHC
+15.65%
3M Return
S
Stonegate Investment Group, LLC
Holding
GEHC
+15.08%
3M Return
N
NewEdge Advisors, LLC
Holding
GEHC
+15.01%
3M Return
S
Salem Investment Counselors, Inc.
Holding
GEHC
+12.78%
3M Return
N
Nippon Life Global Investors Americas, Inc.
Holding
GEHC
+12.57%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GE Healthcare Technologies Inc (GEHC) stock price today?

The current price of GEHC is 62.34 USD — it has decreased -0.83

What is GE Healthcare Technologies Inc (GEHC)'s business?

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

What is the price predicton of GEHC Stock?

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GE Healthcare Technologies Inc (GEHC)'s revenue for the last quarter?

GE Healthcare Technologies Inc revenue for the last quarter amounts to 5.13B USD, increased 7.41

What is GE Healthcare Technologies Inc (GEHC)'s earnings per share (EPS) for the last quarter?

GE Healthcare Technologies Inc. EPS for the last quarter amounts to 0.85 USD, decreased -30.89

How many employees does GE Healthcare Technologies Inc (GEHC). have?

GE Healthcare Technologies Inc (GEHC) has 54000 emplpoyees as of June 01 2026.

What is GE Healthcare Technologies Inc (GEHC) market cap?

Today GEHC has the market capitalization of 28.36B USD.